BioInvent International AB (publ)

SSE:BINV.ST

16.58 (SEK) • At close February 20, 2024
Bedrijfsnaam BioInvent International AB (publ)
Symbool BINV.ST
Munteenheid SEK
Prijs 16.58
Beurswaarde 1,091,036,952
Dividendpercentage 0%
52-weken bereik 14 - 32
Industrie Biotechnology
Sector Healthcare
CEO Dr. Martin Welschof Ph.D.
Website https://www.bioinvent.com

An error occurred while fetching data.

Over BioInvent International AB (publ)

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells;

Vergelijkbare Aandelen

Hansa Biopharma AB (publ) logo

Hansa Biopharma AB (publ)

HNSA.ST

32.64 SEK

Q-linea AB (publ) logo

Q-linea AB (publ)

QLINEA.ST

2.49 SEK

Humana AB (publ) logo

Humana AB (publ)

HUM.ST

27 SEK

Elos Medtech AB (publ) logo

Elos Medtech AB (publ)

ELOS-B.ST

203 SEK

RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST

92.2 SEK

Vicore Pharma Holding AB (publ) logo

Vicore Pharma Holding AB (publ)

VICO.ST

14.38 SEK

Intervacc AB (publ) logo

Intervacc AB (publ)

IVACC.ST

3.735 SEK

IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

IRLAB-A.ST

14.45 SEK

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)